Nautilus Biotechnology (NAUT) Competitors $0.72 +0.01 (+0.92%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.75 +0.03 (+3.77%) As of 08/14/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAUT vs. SENS, QTRX, QSI, FEIM, MASS, KEQU, RPID, SEER, OWLT, and PREShould you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Senseonics (SENS), Quanterix (QTRX), Quantum-Si (QSI), Frequency Electronics (FEIM), 908 Devices (MASS), Kewaunee Scientific (KEQU), Rapid Micro Biosystems (RPID), Seer (SEER), Owlet (OWLT), and Prenetics Global (PRE). These companies are all part of the "measuring and control equipment" industry. Nautilus Biotechnology vs. Its Competitors Senseonics Quanterix Quantum-Si Frequency Electronics 908 Devices Kewaunee Scientific Rapid Micro Biosystems Seer Owlet Prenetics Global Senseonics (NYSE:SENS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Does the media prefer SENS or NAUT? In the previous week, Senseonics had 4 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Senseonics and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.88 beat Senseonics' score of 0.03 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Senseonics Neutral Nautilus Biotechnology Very Positive Which has stronger valuation & earnings, SENS or NAUT? Senseonics has higher revenue and earnings than Nautilus Biotechnology. Senseonics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenseonics$25.47M12.35-$60.39M-$0.10-4.81Nautilus BiotechnologyN/AN/A-$70.78M-$0.52-1.39 Do analysts rate SENS or NAUT? Senseonics presently has a consensus target price of $1.55, suggesting a potential upside of 222.31%. Nautilus Biotechnology has a consensus target price of $2.13, suggesting a potential upside of 194.40%. Given Senseonics' stronger consensus rating and higher possible upside, research analysts clearly believe Senseonics is more favorable than Nautilus Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senseonics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals hold more shares of SENS or NAUT? 12.4% of Senseonics shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 4.3% of Senseonics shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is SENS or NAUT more profitable? Nautilus Biotechnology has a net margin of 0.00% compared to Senseonics' net margin of -362.30%. Nautilus Biotechnology's return on equity of -32.53% beat Senseonics' return on equity.Company Net Margins Return on Equity Return on Assets Senseonics-362.30% -842.25% -67.99% Nautilus Biotechnology N/A -32.53%-27.85% Which has more volatility & risk, SENS or NAUT? Senseonics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. SummarySenseonics and Nautilus Biotechnology tied by winning 8 of the 16 factors compared between the two stocks. Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAUT vs. The Competition Export to ExcelMetricNautilus BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.33M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.3920.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book0.508.608.826.15Net Income-$70.78M-$54.65M$3.25B$265.06M7 Day Performance-1.26%5.86%3.70%2.60%1 Month Performance0.25%8.86%5.84%2.83%1 Year Performance-68.75%13.33%29.92%25.58% Nautilus Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAUTNautilus Biotechnology2.8372 of 5 stars$0.72+0.9%$2.13+194.4%-67.8%$90.33MN/A-1.39130Positive NewsGap UpSENSSenseonics2.3003 of 5 stars$0.51+3.9%$1.55+205.2%+22.3%$332.21M$23.68M-3.9190QTRXQuanterix2.1353 of 5 stars$6.04+3.1%$13.50+123.5%-59.5%$292.73M$137.42M-4.65460QSIQuantum-Si3.0484 of 5 stars$1.44-1.4%$3.48+141.3%+27.2%$267.91M$3.06M-2.12150FEIMFrequency Electronics1.5028 of 5 stars$27.73+4.8%N/A+157.7%$257.30M$69.81M11.23200News CoverageMASS908 Devices3.1041 of 5 stars$6.52+1.6%$5.33-18.2%+70.4%$230.23M$59.63M-12.0760Analyst ForecastKEQUKewaunee Scientific2.3423 of 5 stars$55.38+1.1%N/A+20.1%$161.44M$240.47M14.461,239Short Interest ↓RPIDRapid Micro Biosystems3.7784 of 5 stars$3.49+5.4%$8.00+129.2%+237.8%$145.08M$28.05M-3.39200News CoverageEarnings ReportSEERSeer0.5686 of 5 stars$2.13flat$3.00+40.8%+25.3%$125.39M$14.17M-1.51160OWLTOwlet3.5654 of 5 stars$7.40+0.1%$10.25+38.5%+64.7%$122.12M$78.10M-5.17106PREPrenetics Global2.2804 of 5 stars$7.82-2.3%$9.00+15.1%+47.3%$103.88M$30.62M-1.961Positive News Related Companies and Tools Related Companies SENS Competitors QTRX Competitors QSI Competitors FEIM Competitors MASS Competitors KEQU Competitors RPID Competitors SEER Competitors OWLT Competitors PRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAUT) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access